SCHEMBL5511124

SCHEMBL5511124

O=c1c2ccccc2nc2n1CCC2Br

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.69
BCHE P06276 2/20 0.69
ATM Q13315 1/20 0.52
KDM4E B2RXH2 7/20 0.50
ALDH1A1 P00352 6/20 0.50
HSD17B10 Q99714 4/20 0.50
TDP1 Q9NUW8 2/20 0.50
CYP1A2 P05177 2/20 0.50
USP2 O75604 1/20 0.50
CFTR P13569 1/20 0.50
ALOX15 P16050 1/20 0.50
HKDC1 Q2TB90 1/20 0.50
GOPC Q9HD26 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KMT2A Q03164 2/20 0.49
HPGD P15428 2/20 0.49
MAPT P10636 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
MEN1 O00255 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5506588 0.91 ACHE (0.62) ACHEBCHEATMKDM4EALDH1A1
SCHEMBL8969391 0.82 ACHE (0.47) ACHEBCHEATMKDM4EALDH1A1
SCHEMBL3892901 0.82 ACHE (1.00) ACHEBCHEATMKDM4EALDH1A1
SCHEMBL29638891 0.82 ACHE (1.00) ACHEBCHEATMKDM4EALDH1A1
SCHEMBL3909641 0.82 ACHE (0.69) ACHEBCHEATMKDM4EALDH1A1
SCHEMBL5511623 0.80 ACHE (0.46) ACHEBCHECYP1A2KMT2AMEN1
SCHEMBL5511711 0.80 ACHE (0.46) ACHEBCHEKDM4EALDH1A1HSD17B10
SCHEMBL5512927 0.80 ACHE (0.46) ACHEBCHEKDM4EALDH1A1HSD17B10
SCHEMBL5513404 0.80 ACHE (0.46) ACHEBCHEKDM4EALDH1A1HSD17B10
SCHEMBL5512717 0.77 ACHE (0.43) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521583-B1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-01-10 EP disclosed
US-7067519-B2 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2006-06-27 US disclosed
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates ACTELION PHARMACEUTICALS, LTD. (CH) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates HCRTR2, HCRTR1, NPY1R ACHE 2967/4885BCHE 2964/4885ATM 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.